SENTI-202 is under clinical development by Senti Biosciences and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SENTI-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SENTI-202 overview
SENTI-202 is under development for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other blood cancers. It is administered through intravenous route. The therapeutic candidate comprises of allogeneic CAR-NK cells genetically modified with gene circuits being developed based on engineered gene circuit technology. It act by targeting cells expressing receptor type tyrosine protein kinase (FLT3) and cells expressing myeloid cell surface antigen (CD33).
Senti Biosciences overview
Senti Biosciences is a biotechnology company that develops a technology platform to design synthetic gene circuits for adaptive cell and gene therapies. It’s pipeline programs include Senti-202 for the treatment of AML MDS and other blood cancers; Senti- 401 for the treatment of CRC and other solid tumors; Senti-301 A for the treatment of HCC and other solid tumors among others. It focuses to develop cell therapeutic programs for the treatment of solid and liquid tumors. Senti Biosciences harnesses its synthetic biology platform to design, develop, and test various genetic circuits to enhance human cell and gene therapies. Senti Biosciences is headquartered in South San Francisco, California, the US.
For a complete picture of SENTI-202’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
